4 results
To assess the safety and efficacy of DBV712 in initiating desensitisation of peanut in children aged 1 to 3 years with peanut allergy, after 12 months of treatment with Epicutaneous Immunotherapy EPIT).
The primary objective of this prospective international multicenter diagnostic study is the comparison of the diagnostic accuracy between copeptin measurement after arginine-stimulation (CAS) and the current best diagnostic test copeptin measurement…
• To evaluate the safety and tolerability of THB001 in cold induced chronic urticaria patients
The objectives of this follow-up study of the EPITOPE study are:• To assess the clinical benefit of Viaskin Peanut after up to 3 years of epicutaneous immunotherapy (EPIT) to induce/maintain desensitization to peanut in peanut-allergic children;• To…